Results and analysis of the application of a consistent targeted therapy in patients with metastatic renal cell carcinoma in Moscow (for the period from June 2005 to July 2015)
https://doi.org/10.17650/1726-9776-2016-12-3-30-39
Abstract
Background. This article is a personal experience of a sequential targeted therapy of tyrosine kinase inhibitors for the period from June 2005 to July 2015.
Objective: evaluation of the results of the consistent application of targeted therapies in Moscow in this period.
Materials and methods. A retrospective analysis of cumulative progression-free survival in 220 patients of 354 patients with mRCC were studied. Was used Statistica 10.0 program.
Results. This article presents an analysis of the effectiveness of treatment and survival of patients receiving this therapy in cancer institutions Department of Health in Moscow.
Conclusion. Using of targeted therapy scheme sunitinib → sorafenib, we see no significant difference sVBP compared with scheme sorafenib → sunitinib with two lines ofsequential therapy tyrosine kinase inhibitors (16.9 and 18.2 months). According to our data total progression-free survival terms as applied to the 1st line of therapy tirosine kinase inhibitors (sunitinib and sorafenib), followed by the appointment pazopanib in the 2nd line (12.5 and 14.4 months) and pazopanib in 1st line followed by the appointment tirazinkinaz inhibitors (sunitinib and sorafenib) in the 2nd line (12.50 and 11.56 months) compared to the preliminary results of a multicenter randomized trial expected SWITCH II also not statistically different.
About the Authors
V. I. Shirokorad
Moscow City Cancer Hospital No 62, Moscow Healthcare Department
Russian Federation
27 Istra Settlement, Moscow Region, 143423
Russian Federation
27 Istra Settlement, Moscow Region, 143423
G. P. Kolesnikov
Moscow City Cancer Hospital No 62, Moscow Healthcare Department
Russian Federation
27 Istra Settlement, Moscow Region, 143423
Russian Federation
27 Istra Settlement, Moscow Region, 143423
S. V. Kostritskiy
Moscow City Cancer Hospital No 62, Moscow Healthcare Department
Russian Federation
27 Istra Settlement, Moscow Region, 143423
Russian Federation
27 Istra Settlement, Moscow Region, 143423
K. Yu. Kashintsev
Moscow City Cancer Hospital No 62, Moscow Healthcare Department
Russian Federation
27 Istra Settlement, Moscow Region, 143423
Russian Federation
27 Istra Settlement, Moscow Region, 143423
D. V. Dolgikh
Moscow City Cancer Hospital No 62, Moscow Healthcare Department
Russian Federation
27 Istra Settlement, Moscow Region, 143423
Russian Federation
27 Istra Settlement, Moscow Region, 143423
References
1. Список литературы
2. Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2014 году-М.: МНИОИ им. П.А. Герцена-филиал ФГБУ «НМИРЦ» Минздрава России - 2015 - 236 с.
3. Sablin M. P., S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni, B. Escudier et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009; 182 (1): 29–34.
4. Dudek A. Z., Zolnieriek J., Dham A., Lindgren B. R., Szczylik C. (2009). Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer 115:61–67.
5. Herrmann E., Marschner N., Grimm M. O., Ohlmann C. H., Hutzschenreuter U., Overkamp F., Groschek M., Blumenstengel K., Pühse G., Steiner T. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol. 2011 Jun; 29 (3):361–6.
6. Buchler T., Klapka R., Melichar B., Brabec P., Dusek L., Vyzula R., Abrahamova J. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma – data from the Czech registry. Ann Oncol. 2012 Feb; 23 (2):395–401.
7. Porta C., Procopio G., Cartenì G., Sabbatini R., Bearz A., Chiappino I., Ruggeri E. M., Re G. L., Ricotta R., Zustovich F., Landi L., Calcagno A., Imarisio I., Verzoni E., Rizzo M., Paglino C,. Guadalupi V., Bajetta E. Sequential use of sorafenib and sunitinib in advanced renalcell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 2011 Oct; 108 (8 Pt 2): E250–7.
8. Maurice Stephan Michel, Vervenne W., de Santis M. et al. SWITCH I: A randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer. J Clin Oncol 2014; 32 (suppl 4; abstract 393), Genitourinary Cancers Symposium.
9. Stenner F., Chastonay R., Liewen H. et al. A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology 2012;82(6): 333–40
10. Di Lorenzo G., Buonerba C., Federico P. et al. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma. Eur Urol 2010;58(6): 906–11
11. Di Lorenzo G., Autorino R., Bruni G. et al. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis. Ann Oncol 2009; 20(9):1535–42.
12. Yuan J.L., Wang F.L., Yi X.M. et al. More than 10 years survival with sequential therapy in a patient with advanced renal cell carcinoma: a case report. Braz J Med Biol Res 2015; 48(1):34–8.
13. Motzer R.J., Hutson T.E., Reeves J. et al. Randomized open-label phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (MRCC): Results of the COMPARZ trial. 2012 ESMO Congress. Abstract LBA8. Presented October 1, 2012.
14. В.И. Широкорад, А.Н. Махсон. Первые результаты таргетной терапии при раке почки в Москве: Онкоурология 3’ 2013г. 24-29 стр.
15. Е.Н. Имянитов., Общие представления о таргетной терапии: Practical oncology, практическая онкология, Т. 11, №3 – 2010.
16. Д.А. Носов, Е.А. Ворошилова. Современное представление об алгоритме лекарственного лечения и оптимальной последовательности использования таргетных препаратов: Онкоурология 3’ 2014г.12-19стр.
17. Choueiri T.K., Brick A.J., Mc Dermott D. et al (2008) Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (mRCC). Ann Oncol 19(Suppl): viii 191 (abstract 593P)
18. Tamaskar I., Garcia J.A., Elson P. et al (2008) Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy. J Urol 179: 81–86.
19. Richter S., Pfister D., Thur D. et al (2009) Second-line treatment of progressive metastatic renal cell cancer with temsirolimus following first-line therapy with sunitinib or sorafenib. Onkologie 31:324 (abstract V684)
20. Kaja Zimmermann, Alexander Schmittel, Ursula Steiner, Anne Marie Asemissen, Maren Knoedler, Eckhard Thiel, Kurt Miller,Ulrich Keilholz (2009), Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 76:350–354
21. Eichelberg C., Heuer R., Chun F.K. et al (2008), Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis. Eur Urol 54:1373–1378
Review
For citations:
Shirokorad V.I., Kolesnikov G.P., Kostritskiy S.V., Kashintsev K.Yu., Dolgikh D.V. Results and analysis of the application of a consistent targeted therapy in patients with metastatic renal cell carcinoma in Moscow (for the period from June 2005 to July 2015). Cancer Urology. 2016;12(3):30-39. https://doi.org/10.17650/1726-9776-2016-12-3-30-39
Views:
1135
Email this article 